Cargando…

Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma

Gemcitabine (Gem)-based chemotherapy is one of the first-line treatments for pancreatic ductal adenocarcinoma (PDAC). However, its clinical effect is limited due to development of chemoresistance. Various naturally occurring compounds, including Berberine (BBR), provide an anti-cancer efficacy with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okuno, Keisuke, Xu, Caiming, Pascual-Sabater, Silvia, Tokunaga, Masanori, Han, Haiyong, Fillat, Cristina, Kinugasa, Yusuke, Goel, Ajay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611392/ https://www.ncbi.nlm.nih.gov/pubmed/36297310 http://dx.doi.org/10.3390/ph15101199

Ejemplares similares

Andrographis Reverses Gemcitabine Resistance through Regulation of ERBB3 and Calcium Signaling Pathway in Pancreatic Ductal Adenocarcinoma
por: Okuno, Keisuke, et al.
Publicado: (2023)

Berberine and Oligomeric Proanthocyanidins Exhibit Synergistic Efficacy Through Regulation of PI3K-Akt Signaling Pathway in Colorectal Cancer
por: Okuno, Keisuke, et al.
Publicado: (2022)

Corrigendum: Berberine and Oligomeric Proanthocyanidins Exhibit Synergistic Efficacy Through Regulation of PI3K-Akt Signaling Pathway in Colorectal Cancer
por: Okuno, Keisuke, et al.
Publicado: (2022)

Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma
por: Takagi, Tadataka, et al.
Publicado: (2023)

Attempts to remodel the pathways of gemcitabine metabolism: Recent approaches to overcoming tumours with acquired chemoresistance
por: Saiki, Yuriko, et al.
Publicado: (2020)

Modified Gold Nanoparticles to Overcome the Chemoresistance to Gemcitabine in Mutant p53 Cancer Cells
por: García-Garrido, Eduardo, et al.
Publicado: (2021)

A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer
por: Okuno, Keisuke, et al.
Publicado: (2023)

Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1– Mediated Gemcitabine Chemoresistance
por: Bai, Zhiqing, et al.
Publicado: (2022)

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma
por: Dhayat, Sameer A., et al.
Publicado: (2015)

Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles
por: Chen, Zhe, et al.
Publicado: (2018)

Prognostic Value of Intraoperative Blood Transfusion in Patients with Adenocarcinoma of the Esophagogastric Junction
por: Nakajima, Kei, et al.
Publicado: (2022)

Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma
por: Zhao, Xianda, et al.
Publicado: (2016)

Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma
por: Rohila, Deepak, et al.
Publicado: (2023)

The Fhit protein: an opportunity to overcome chemoresistance
por: Gaudio, Eugenio, et al.
Publicado: (2016)

Cisplatin for cancer therapy and overcoming chemoresistance
por: Ranasinghe, Ranmali, et al.
Publicado: (2022)

Down-regulation of miR-30a-5p is Associated with Poor Prognosis and Promotes Chemoresistance of Gemcitabine in Pancreatic Ductal Adenocarcinoma
por: Zhou, Liangjing, et al.
Publicado: (2019)

Interstitial Flow Recapitulates Gemcitabine Chemoresistance in A 3D Microfluidic Pancreatic Ductal Adenocarcinoma Model by Induction of Multidrug Resistance Proteins
por: Kramer, Bart, et al.
Publicado: (2019)

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
por: Nakano, Y, et al.
Publicado: (2007)

Minimally Invasive Surgery for Colorectal Cancer
por: Yamauchi, Shinichi, et al.
Publicado: (2021)

Ets-1 expression and gemcitabine chemoresistance in pancreatic cancer cells
por: Khanna, Amit, et al.
Publicado: (2010)

Targeting Cancer Stem Cells to Overcome Chemoresistance
por: Nunes, Toni, et al.
Publicado: (2018)

Disrupting the endothelin and Wnt relationship to overcome chemoresistance
por: Rosanò, Laura, et al.
Publicado: (2015)

Overcoming Chemoresistance via Extracellular Vesicle Inhibition
por: Hayatudin, Raeesah, et al.
Publicado: (2021)

Editorial: Strategies in overcoming the chemoresistance in colorectal cancer
por: Vodenkova, Sona, et al.
Publicado: (2023)

An exosome-based liquid biopsy signature for pre-operative identification of lymph node metastasis in patients with pathological high-risk T1 colorectal cancer
por: Miyazaki, Katsuki, et al.
Publicado: (2023)

Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
por: Comandatore, Annalisa, et al.
Publicado: (2022)

Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma
por: Ramani, Vishnu C., et al.
Publicado: (2015)

Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma
por: Salaroglio, Iris Chiara, et al.
Publicado: (2014)

Mitochondria: Insights into Crucial Features to Overcome Cancer Chemoresistance
por: Genovese, Ilaria, et al.
Publicado: (2021)

Albumin nanoformulations as an innovative solution to overcome doxorubicin chemoresistance
por: Bessone, Federica, et al.
Publicado: (2021)

Eggmanone Effectively Overcomes Prostate Cancer Cell Chemoresistance
por: Xie, Chen, et al.
Publicado: (2021)

Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma
por: Acuna-Villaorduna, Ana, et al.
Publicado: (2022)

IGF-1R: SUMO-ing its weight in chemoresistant colorectal cancer
por: Goel, Ajay
Publicado: (2017)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

Role of epithelial-mesenchymal transition in chemoresistance in pancreatic ductal adenocarcinoma
por: Hu, Xiu, et al.
Publicado: (2021)

BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer
por: Nakashima, Shinsuke, et al.
Publicado: (2015)

Overcoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling
por: Phi, Ji Hoon, et al.
Publicado: (2015)

Targeted multidrug delivery system to overcome chemoresistance in breast cancer
por: Tang, Yuan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bpco8hleb8nqagbjipobk7p4a0